Navigation Links
Vion in Medical News

Vion Pharmaceuticals to Present Data on Onrigin(TM)at the ASCO(R) Annual Meeting

...AVEN, Conn., May 29 /PRNewswire-FirstCall/ -- vion PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) ...0, 2009. A copy of the poster will be available on vion Pharmaceuticals' website, www.vionpharm.com , o...2:00 p.m. on Saturday, May 30, 2009. About vion ...

Vion Pharmaceuticals Reports 2009 First Quarter Results

...EW HAVEN, Conn., May 11 /PRNewswire-FirstCall/ -- vion PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) ...ilable through Thursday, May 28, 2009. About vion vion Pharmaceuticals, Inc. is committed to extending th...

Vion Pharmaceuticals Receives a Standard Review from the FDA for Its New Drug Application for Onrigin(TM)

... HAVEN, Conn., April 23 /PRNewswire-FirstCall/ -- vion PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) ...to have an FDA decision this year." About vion Pharmaceuticals vion Pharmaceuticals, Inc. is committed to extending th...

Vion Pharmaceuticals' New Drug Application for Onrigin(TM)Accepted For Review by the FDA

... HAVEN, Conn., April 16 /PRNewswire-FirstCall/ -- vion Pharmaceuticals, Inc. (OTC Bulletin Board: VION) ...rst indication in the United States." About vion Pharmaceuticals vion Pharmaceuticals, Inc. is committed to extending th...

Vion Updates Conference Call Information

...hrough Thursday, November 20, 2008. About Vion vion Pharmaceuticals, Inc. is committed to extending th...nd commercializing innovative cancer therapeutics. vion has two agents in clinical trials. Laromustine (Cl...al Cancer Institute. For additional information on vion and its product development programs, visit the Co...

Vion Reports 2008 Third Quarter and Nine-Month Results

...hrough Thursday, November 20, 2008. About Vion vion Pharmaceuticals, Inc. is committed to extending th...nd commercializing innovative cancer therapeutics. vion has two agents in clinical trials. Laromustine (Cl...al Cancer Institute. For additional information on vion and its product development programs, visit the Co...

Vion Reports 2008 Second Quarter and Six-Month Results

...FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: vion ) today announced financial results for the three-... through Thursday, August 21, 2008. About Vion vion Pharmaceuticals, Inc. is committed to extending th...nd commercializing innovative cancer therapeutics. vion has two agents in clinical trials. Cloretazine(R) ...

BeaconEquity.com Issues TraderNotes on Biotechnology Stocks: TPIM, RXII, VION, CUR, AMGN, GILD, BIIB, GENR

...nc. (OTC Bulletin Board: TPIM), RXi Pharmaceuticals Corp. (Nasdaq: RXII ), vion Pharmaceuticals Inc. (Nasdaq: vion ), Neuralstem Inc. (Amex: CUR ), Amgen Inc. (Nasdaq: AMGN ), Gilead Scien...

Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting

...FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: vion ) today announced that data from the Phase III tri...presentation of the unblinded data. About Vion vion Pharmaceuticals, Inc. is committed to extending th...nd commercializing innovative cancer therapeutics. vion has two agents in clinical trials. Cloretazine(R) ...

Vion Pharmaceuticals to Appeal Nasdaq Delisting

... NEW HAVEN, Conn., May 8 /PRNewswire-FirstCall/ -- vion PHARMACEUTICALS, INC. (Nasdaq: vion ) today announced that it had received a letter, d...ant the Company's request for continued listing. vion Pharmaceuticals, Inc. is committed to extending th...
Vion in Medical Technology

Vion Pharmaceuticals Enters into Agreement to Conduct a Phase I/II Clinical Trial of Cloretazine(R) in Combination with Induction Therapy in Poor Prognosis AML Patients

...nducted at various sites in France. About Vion vion Pharmaceuticals, Inc. is committed to extending th...nd commercializing innovative cancer therapeutics. vion has two agents in clinical trials. Laromustine (Cl...al Cancer Institute. For additional information on vion and its product development programs, visit the Co...

Vion Pharmaceuticals Enters Into Agreement With HOVON to Conduct a Phase III Clinical Trial of Cloretazine(R) in Combination With Frontline AML and MDS Therapy

...s, Belgium, Switzerland and Norway. About Vion vion Pharmaceuticals, Inc. is committed to extending th...nd commercializing innovative cancer therapeutics. vion has two agents in clinical trials. Laromustine (Cl...al Cancer Institute. For additional information on vion and its product development programs, visit the Co...

Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting

...FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: vion ) today announced that data from a previously cond...g/m2 of Cloretazine(R) (VNP40101M). About Vion vion Pharmaceuticals, Inc. is committed to extending th...nd commercializing innovative cancer therapeutics. vion has two agents in clinical trials. Cloretazine(R) ...

Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting

...FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: vion ) today announced that interim data from the pivot...gy Annual Meeting in December 2007. About Vion vion Pharmaceuticals, Inc. is committed to extending th...nd commercializing innovative cancer therapeutics. vion has two agents in clinical trials. Cloretazine(R) ...

Vion Pharmaceuticals to Present Clinical Data on Cloretazine(R) (VNP40101M) at the ASCO(R) Annual Meeting

...FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: vion ) today announced that data from two clinical tria...1, 2008. A copy of the poster will be available on vion Pharmaceuticals' website, http://www.vionpharm.co...m E354a. A copy of the poster will be available on vion Pharmaceuticals' website, http://www.vionpharm.co...

Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine

... NEW HAVEN, Conn., May 8 /PRNewswire-FirstCall/ -- vion PHARMACEUTICALS, INC. (Nasdaq: vion ) today announced the start of an investigator-spo... as well as improve the quality of their lives." vion Pharmaceuticals, Inc. is committed to extending th...

Vion Pharmaceuticals Announces FDA Lift of Clinical Hold on Phase III Study of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed AML

...FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: vion ) today announced that the U.S. Food and Drug Admi...ewers performed a comprehensive safety analysis of vion Study CLI-037. This analysis concluded that the co...(R)) in December 2007. Conference Call Details vion will hold a conference call on Tuesday, January 8,...

Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) at the American Society of Hematology Meeting

...FirstCall/ -- Vion Pharmaceuticals, Inc. (Nasdaq: vion ) today announced that preliminary data from its p... poster. A copy of the poster will be available on vion Pharmaceuticals' website, http://www.vionpharm.co... be available through Monday, December 24, 2007. vion Pharmaceuticals, Inc. is committed to extending th...

Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Stem Cell Transplantation

...ntribution in the stem cell transplant setting." vion Pharmaceuticals, Inc. is committed to extending th...nd commercializing innovative cancer therapeutics. vion has two agents in clinical trials. Cloretazine(R) ...al Cancer Institute. For additional information on vion and its product development programs, visit the Co...

Vion Pharmaceuticals Announces Initiation of a Phase I/II Trial of Cloretazine(R) (VNP40101M) in Combination with Temodar(R) in Adult Brain Tumors

...FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: vion ) today announced that an investigator-sponsored t...of Clinical Oncology Annual Meeting in June 2007. vion Pharmaceuticals, Inc. is committed to extending th...nd commercializing innovative cancer therapeutics. vion has two agents in clinical trials. Cloretazine(R) ...
Vion in Biological Technology

Vion Pharmaceuticals Submits New Drug Application for Onrigin(TM)

...W HAVEN, Conn., Feb. 17 /PRNewswire-FirstCall/ -- vion PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) ...d, "This NDA filing is a significant milestone for vion and for the Onrigin clinical development program. ...tions are needed for this population. About vion ...

Vion Pharmaceuticals to Present Survival Data on Laromustine at ASH Annual Meeting

...EW HAVEN, Conn., Dec. 4 /PRNewswire-FirstCall/ -- vion PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) ...an Francisco from December 6-9, 2008. vion Poster Presentation The Company announc... New Trade Name for Laromustine vion will introduce Onrigin(TM) as the new trade name f...

Vion Reports 2008 First Quarter Results

... NEW HAVEN, Conn., May 5 /PRNewswire-FirstCall/ -- vion PHARMACEUTICALS, INC. (Nasdaq: vion ) today announced financial results for the three-...ained herein are provided on a post-split basis. vion Pharmaceuticals, Inc. is committed to extending th...

Vion Pharmaceuticals Files Plan With Nasdaq

...FirstCall/ -- Vion Pharmaceuticals, Inc. (Nasdaq: vion ) today announced that it had filed a plan to achi...cision to a Nasdaq Listing Qualifications Panel. vion Pharmaceuticals, Inc. is committed to extending th...nd commercializing innovative cancer therapeutics. vion has two agents in clinical trials. Cloretazine(R) ...

Vion Reports 2007 Fourth Quarter and Year-End Results

...ained herein are provided on a post-split basis. vion Pharmaceuticals, Inc. is committed to extending th...nd commercializing innovative cancer therapeutics. vion has two agents in clinical trials. Cloretazine(R) ...nce of unanticipated events. COMPANY CONTACT: vion Pharmaceuticals, Inc. Alan Kess...

Vion Pharmaceuticals to Host Conference Call to Discuss 2007 Fourth Quarter and Year-End Financial Results

...ill be available through Tuesday, April 1, 2008. vion Pharmaceuticals, Inc. is committed to extending th...nd commercializing innovative cancer therapeutics. vion has two agents in clinical trials. Cloretazine(R) ...al Cancer Institute. For additional information on vion and its product development programs, visit the Co...

Vion Pharmaceuticals to Implement a One-for-Ten Reverse Stock Split

...FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: vion ) today announced that the Company would implement...nesday, February 20, 2008. On a pre-split basis, vion Pharmaceuticals has 81,017,569 shares outstanding ...ult of the reverse stock split, every 10 shares of vion Common Stock will be combined into one share of...

Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes

...FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: vion ) today announced that the Company had paid intere... interest was paid in lieu of fractional shares. vion Pharmaceuticals, Inc. is committed to extending th...nd commercializing innovative cancer therapeutics. vion has two agents in clinical trials. Cloretazine(R) ...

Vion Pharmaceuticals Holds Special Meeting of Stockholders

...FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: vion ) announced that a Special Meeting of Stockholders... compliance with Nasdaq's listing requirements." vion Pharmaceuticals, Inc. is committed to extending th...nd commercializing innovative cancer therapeutics. vion has two agents in clinical trials. Cloretazine(R) ...

Vion Pharmaceuticals Adds William Hahne, M.D. to Senior Management Team

...FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: vion ) today announced that William Hahne, M.D. has joi...e are extremely pleased to have Bill Hahne joining vion in medical affairs. He has a wealth of experience ...ersity Affiliated Hospitals in Atlanta, Georgia. vion Pharmaceuticals, Inc. is committed to extending th...
Other Tags
(Date:1/22/2015)... January 22, 2015 Four years since the release ... which coincided with the marriage of Avasa & Matthew Love – ... which is scheduled for release through White Swan Records on February ... there is a sacred path available to all of us to ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 EBSCO Information ... (AMA) are expanding their relationship in an effort to further ... the world. While EBSCO has long made AMA journals available ... sales agent for The JAMA Network. , Long ...
(Date:1/22/2015)... JJsHouse.com is a famous dress online store for wedding dresses ... latest collection of wedding dresses , and launches a site-wide ... wedding dress on your big day; the wedding gown is ... wants to find the most suitable wedding dress. Now, we ...
(Date:1/22/2015)... January 22, 2015 Lower-Auto-Insurance.com has released a new ... in a car for reducing the costs of an auto ... also be able to get lower prices for their vehicle insurance ... important role in determining policy costs. Because of this, drivers ...
(Date:1/22/2015)... Ga., USA (PRWEB) January 22, 2015 ... a statewide data management system with support from GEOSYSTEMS, ... , The new solution will leverage Hexagon Geospatial’s ... and vector data as well as point clouds and ...
Breaking Medicine News(10 mins):Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 3
(Date:1/22/2015)... POINT ROBERTS, Washington , January 20, 2015 ... including technology and tech stocks, releases video from the CES ... and security consultant Apollo Robbins . Apollo ... the Wocket™ biometric smart wallet, a product of NXT-ID, Inc. ...
(Date:1/22/2015)... DUBLIN , Jan. 22, 2015 Research and ... the addition of the "Global Wearable Technologies ... Growth, Share, Overview, Trends and Forecast 2014-2020" ... Wearable Technologies are smart devices that can be ...
(Date:12/24/2014)... , Dec. 23, 2014  Since its launch in December 2014, the ... eliminate the pain of trying to remember their usernames and ... fused to their smartphones. To assist people who have struggled ... company that created 1U and focuses on redefining identity, announced ...
Breaking Biology News(10 mins):Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3
Other Contents